Identification of cross-reactive T cell restriction epitopes located on the DR7 beta 1 and DR beta 4 molecules.
L cell fibroblasts transfected with HLA class II cDNA clones isolated from a cDNA library produced from a DR7 homozygous cell line were used as antigen-presenting cells (APC) for three HLA DR-restricted, diphtheria toxoid-specific T-cell clones in order to assess the antigen-presenting ability of the transfectants and to define the class II restriction of each clone. Class II-expressing transfectants are capable of presenting antigen to antigen-specific T-cell clones, although the transfectants are less efficient at antigen presentation than conventional APC. Paraformaldehyde fixation of transfectants prior to antigen pulsing abrogated antigen presentation, demonstrating that the transfectants require antigen processing. Antigen presentation by transfectants is completely inhibited by CD4-specific monoclonal antibodies (mAb) and one of four DR-specific mAb, whereas antigen presentation by conventional APC is only partially inhibited. Both the DR alpha:DR7 beta 1 and DR alpha:DR beta 4 (DR omega 53) molecules of the DR7 allotype serve as restriction elements for the diphtheria toxoid-specific T-cell clones. One clone is restricted by the DR7 beta 1 molecule, another clone by the DR beta 4(DR omega 53) molecule, and a third clone by a cross-reactive T cell epitope on DR7 beta 1 and DR beta 4(DR omega 53) molecules. The two DR beta 4(DR omega 53)-restricted clones react, however, differently with a panel of HLA-DR DR omega 53-positive human peripheral blood lymphocytes used as APC. Therefore the data presented here clearly document that the DR beta 4 (DR omega 53) chain may serve as restriction elements for DT-specific T-cell clones. They also provide the first evidence for functional cross-reactivity of the products of two different DR beta loci and in addition emphasize the high complexity of the supertypic HLA-DR omega 53 specificity.
Laboratoire d'Immunologie Cellulaire et Tissulaire, CNRS UA 186, Hôpital de la Pitié-Salpêtrière, Paris, France.
G
G
Bismuth
H
H
Gouy
R W
RW
Karr
P
P
Debré
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000938:Antigen-Presenting Cells / Q000276:immunology; D002461:Cell Line, Transformed; D003429:Cross Reactions / Q000276:immunology*; D004168:Diphtheria Toxoid / Q000276:immunology; D000939:Epitopes / Q000276:immunology*; D005347:Fibroblasts / Q000166:cytology; D005557:Formaldehyde / Q000494:pharmacology; D006684:HLA-DR Antigens / Q000276:immunology*; D015809:HLA-DR7 Antigen / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D011108:Polymers / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology*; D014162:Transfection / Q000235:genetics
D000911:Antibodies, Monoclonal; D004168:Diphtheria Toxoid; D000939:Epitopes; D006684:HLA-DR Antigens; D015809:HLA-DR7 Antigen; D000949:Histocompatibility Antigens Class II; D011108:Polymers; D005557:Formaldehyde; C003043:paraform